Roivant Sciences Ltd (NAS:ROIV)
$ 11.57 -0.26 (-2.2%) Market Cap: 8.56 Bil Enterprise Value: 3.46 Bil PE Ratio: 2.08 PB Ratio: 1.58 GF Score: 59/100

Q2 2020 Sumitomo Dainippon Pharma Co Ltd Earnings Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences Transcript

Nov 01, 2019 / 04:00AM GMT

Nov 01, 2019 / 04:00AM GMT
Presentation and Definitive Agreement for Strategic Alliance with Roivant Sciences
Nov 01, 2019 / 04:00AM GMT

=====================
Corporate Participants
=====================
* Hiroshi Nomura
Sumitomo Dainippon Pharma Co., Ltd. - CEO, President & Representative Director

=====================
Conference Call Participants
=====================
* Fumiyoshi Sakai
Crédit Suisse AG, Research Division - Research Analyst
* Kazuaki Hashiguchi
Daiwa Securities Co. Ltd., Research Division - Research Analyst
* Motoya Kohtani
Nomura Securities Co. Ltd., Research Division - Senior Analyst
* Seiji Wakao
Mitsubishi UFJ Morgan Stanley Securities Co., Ltd., Research Division - Senior Analyst
* Shinichiro Muraoka
Morgan Stanley, Research Division - Research Analyst
* Stephen Marks
Jefferies LLC - Investment Banking Analyst
* Yasuhiro Nakazawa
SMBC Nikko Securities Inc., Research Division - Senior Analyst
* Myrtle Potter;CEO
* Vivek Ramaswamy
Roivant

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot